SAREPTA THERAPEUTICS, INC. (SRPT) Total liabilities 2016–2025
SAREPTA THERAPEUTICS, INC. (SRPT) total liabilities at each fiscal year-end, per SEC filings.
$2.2BFY2025 · since FY2016: $87.4M → $2.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.2B | -9.3% |
| FY2024 | $2.4B | +1.3% |
| FY2023 | $2.4B | -12.3% |
| FY2022 | $2.7B | +23.6% |
| FY2021 | $2.2B | -0.1% |
| FY2020 | $2.2B | +121.3% |
| FY2019 | $1.0B | +64.7% |
| FY2018 | $609.8M | +17.6% |
| FY2017 | $518.7M | +493.4% |
| FY2016 | $87.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SRPT financial trends
SRPT RevenueSRPT Net incomeSRPT Net marginSRPT Gross profitSRPT Gross marginSRPT Operating incomeSRPT Operating marginSRPT Operating cash flowSRPT Free cash flowSRPT Capital expendituresSRPT Return on equitySRPT Stock buybacksSRPT Dividends paidSRPT Total assetsSRPT Shareholders’ equitySRPT overview →